Cargando…
Pamrevlumab, a Fully Human Monoclonal Antibody Targeting Connective Tissue Growth Factor, for Non-Ambulatory Patients with Duchenne Muscular Dystrophy
BACKGROUND: Duchenne muscular dystrophy (DMD) is a neuromuscular disease stemming from dystrophin gene mutations. Lack of dystrophin leads to progressive muscle damage and replacement of muscle with fibrotic and adipose tissue. Pamrevlumab (FG-3019), a fully human monoclonal antibody that binds to c...
Autores principales: | Connolly, Anne M., Zaidman, Craig M., Brandsema, John F., Phan, Han C., Tian, Cuixia, Zhang, Xueping, Li, Jack, Eisner, Mark D., Carrier, Ewa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357134/ https://www.ncbi.nlm.nih.gov/pubmed/37248912 http://dx.doi.org/10.3233/JND-230019 |
Ejemplares similares
-
Medical management of muscle weakness in Duchenne muscular dystrophy
por: Rivera, Sarah R., et al.
Publicado: (2020) -
Evaluating a Stone of Hope: ICER’s 2019 Review of Treatments for Duchenne Muscular Dystrophy
por: Brandsema, John Frederick
Publicado: (2020) -
Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy
por: Khan, Navid, et al.
Publicado: (2019) -
Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy
por: Clemens, Paula R., et al.
Publicado: (2022) -
Ambulatory Monitoring and Arrhythmic Outcomes in Pediatric and Adolescent Patients With Duchenne Muscular Dystrophy
por: Villa, Chet R., et al.
Publicado: (2015)